Prospective analysis of bleomycin electrosclerotherapy for clinical outcome and volume reduction in therapy refractory slow-flow malformations
Bleomycin electrosclerotherapy demonstrated high effectiveness and safety for treating slow-flow malformations, establishing it as a promising therapeutic option even for lesions that have responded insufficiently to previous treatment attempts.
Authors
- Marie-Sophie Schüngel
- Vanessa F. Schmidt (ORCID: https://orcid.org/0000-0002-7067-2203)
- Oleksandr Bidakov (ORCID: https://orcid.org/0009-0009-1287-5991)
- Moritz Wildgruber (ORCID: https://orcid.org/0000-0002-7228-6963)
- Moritz Guntau
- Constantin Goldann (ORCID: https://orcid.org/0000-0002-2133-7935)
- Julius Henry Loeser (ORCID: https://orcid.org/0009-0003-8644-690X)
- Walter Alexander Wohlgemuth (ORCID: https://orcid.org/0000-0002-8076-6000)
- Anna Deleu
- Richard Brill
Institutions
- LMU Klinikum (DE)
- Universitätsklinikum Würzburg (DE)
- München Klinik Harlaching (DE)
- University Hospital in Halle (DE)
- Technical University of Munich (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- CVIR Endovascular
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1186/s42155-025-00641-z
- Primary Topic
- Vascular Malformations and Hemangiomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00